Logotipo del repositorio
Logotipo del repositorio
 

Impacto de las estrategias de afrontamiento y la calidad de vida sobre la adherencia al tratamiento en pacientes con nefritis lúpica

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_f1cf
dc.contributor.advisorÁngeles Depine, Santos
dc.contributor.advisorAroca Martínez, Gustavo
dc.contributor.advisorGonzález Torres, Henry Joseth
dc.contributor.authorHernández Rosero, Kelly Katherin
dc.date.accessioned2026-02-05T19:32:17Z
dc.date.available2026-02-05T19:32:17Z
dc.date.issued2025
dc.description.abstractLa nefritis lúpica constituye una de las manifestaciones más graves del lupus eritematoso sistémico, asociada a un mayor riesgo de progresión a enfermedad renal crónica y a una elevada carga terapéutica. En este contexto, la adherencia al tratamiento representa un componente crítico del manejo clínico; sin embargo, su comportamiento está influenciado no solo por factores biomédicos, sino también por variables psicosociales, como la calidad de vida relacionada con la salud y las estrategias de afrontamiento. En el Caribe colombiano, la evidencia local que explore de manera integrada estos factores es limitada. Objetivo: Evaluar la relación entre las estrategias de afrontamiento individuales, la calidad de vida relacionada con la salud y la adherencia al tratamiento en pacientes con nefritis lúpica atendidos en una clínica de referencia en Barranquilla (Atl, CO) durante 2022–2023.spa
dc.description.abstractLupus nephritis is one of the most severe manifestations of systemic lupus erythematosus and is associated with an increased risk of progression to chronic kidney disease and a high therapeutic burden. In this context, treatment adherence represents a critical component of clinical management; however, adherence behavior is influenced not only by biomedical factors but also by psychosocial variables, such as health-related quality of life and coping strategies. In the Colombian Caribbean region, local evidence exploring these factors in an integrated manner remains limited. Objective: To evaluate the relationship between individual coping strategies, healthrelated quality of life, and treatment adherence in patients with lupus nephritis treated at a referral clinic in Barranquilla (Atl, CO) during 2022–2023.eng
dc.format.mimetypepdf
dc.identifier.urihttps://hdl.handle.net/20.500.12442/17337
dc.language.isospa
dc.publisherEdiciones Universidad Simón Bolívarspa
dc.publisherFacultad de Ciencias de la Saludspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationaleng
dc.rights.accessrightsinfo:eu-repo/semantics/embargoedAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectNefritis lúpicaspa
dc.subjectAdherencia al tratamientospa
dc.subjectCalidad de vida relacionada con la saludspa
dc.subjectEstrategias de afrontamientospa
dc.subjectLupus eritematoso sistémicospa
dc.subjectResultados reportados por el pacientespa
dc.subjectCaribe Colombianospa
dc.subject.keywordslupus nephritiseng
dc.subject.keywordstreatment adherenceeng
dc.subject.keywordshealth-related quality of lifeeng
dc.subject.keywordscoping strategieseng
dc.subject.keywordssystemic lupus erythematosuseng
dc.subject.keywordspatient-reported outcomeseng
dc.subject.keywordsColombian Caribbeaneng
dc.titleImpacto de las estrategias de afrontamiento y la calidad de vida sobre la adherencia al tratamiento en pacientes con nefritis lúpicaspa
dc.type.driverinfo:eu-repo/semantics/other
dc.type.spaOtros
dcterms.referencesMehat P, Atiquzzaman M, Esdaile JM, AviÑa-Zubieta A, De Vera MA. Medication Nonadherence in Systemic Lupus Erythematosus: A Systematic Review. Arthritis Care Res (Hoboken) 2017;69:1706–13. https://doi.org/10.1002/acr.23191.eng
dcterms.referencesCostedoat-Chalumeau N, Houssiau FA. Improving medication adherence in patients with lupus nephritis. Kidney Int 2021;99:285–7. https://doi.org/10.1016/j.kint.2020.10.037.eng
dcterms.referencesDomínguez-Vargas A, González-Torres H, Martínez-Bayona Á, SanguinoJaramillo M, Vélez-Verbel M, Cadena-Bonfanti A, et al. Treatment adherence and quality of life in colombian patients with lupus nephritis. Lupus 2024;33:1317–27. https://doi.org/10.1177/09612033241280548.eng
dcterms.referencesElera-Fitzcarrald C, Fuentes A, González LA, Burgos PI, Alarcón GS, UgarteGil MF. Factors affecting quality of life in patients with systemic lupus erythematosus: important considerations and potential interventions. Expert Rev Clin Immunol 2018;14:915–31. https://doi.org/10.1080/1744666X.2018.1529566.eng
dcterms.referencesEtchegaray-Morales I, Méndez-Martínez S, Jiménez-Hernández C, MendozaPinto C, Alonso-García NE, Montiel-Jarquín A, et al. Factors Associated with Health-Related Quality of Life in Mexican Lupus Patients Using the LupusQol. PLoS One 2017;12:e0170209. https://doi.org/10.1371/journal.pone.0170209.eng
dcterms.referencesMachado Escobar MA, Yacuzzi MS, Martinez RN, González Lucero L, Bellomio VI, Santana M, et al. Validation of an Argentine version of Lupus Quality of Life questionnaire. Lupus 2016;25:1615–22. https://doi.org/10.1177/0961203316660202.eng
dcterms.referencesCornet A, Mazzoni D, Edwards A, Monzani D, Pravettoni G, Andersen J, et al. Coping with systemic lupus erythematosus in patients’ words. Lupus Sci Med 2022;9. https://doi.org/10.1136/lupus-2022-000656.eng
dcterms.referencesGaviria Garcia GG, Sierra Llamas C, Aroca Martínez G, Lastre Amell G. Valorar el seguimiento y cumplimiento integral de adherencia al tratamiento en pacientes con nefritis lúpica. Investig En Enfermería Imagen y Desarro 2018;20. https://doi.org/10.11144/Javeriana.ie20-1.vsci.spa
dcterms.referencesGBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England) 2020;395:709–33. https://doi.org/10.1016/S0140-6736(20)30045-3.eng
dcterms.referencesKidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2024;105:S117–314. https://doi.org/10.1016/j.kint.2023.10.018.eng
dcterms.referencesPollak MR, Friedman DJ. APOL1 and APOL1-Associated Kidney Disease: A Common Disease, an Unusual Disease Gene - Proceedings of the Henry Shavelle Professorship. Glomerular Dis 2023;3:75–87. https://doi.org/10.1159/000529227.eng
dcterms.referencesPereira-Morales AJ, Buelvas W, De la Espriella V, Montenegro A, Rojas LH, Amador W. Factors Associated with Accelerated Progression of Chronic Kidney Disease in Patients from the Colombian Caribbean Coast. Rev Colomb Nefrol 2023;10. https://doi.org/10.22265/acnef.10.1.630.eng
dcterms.referencesSoliman S, Ahmed RM, Ahmed MM, Attia A, Soliman AR. Non-steroidal antiinflammatory drugs: what is the actual risk of chronic kidney disease? A systematic review and meta-analysis. Rom J Intern Med 2025;63:3–27. https://doi.org/10.2478/rjim-2024-0029.eng
dcterms.referencesCalvert GM. Agricultural pesticide exposure and chronic kidney disease: new findings and more questions. Occup Environ Med 2016;73:1–2. https://doi.org/10.1136/oemed-2015-103132.eng
dcterms.referencesValcke M, Levasseur M-E, Soares da Silva A, Wesseling C. Pesticide exposures and chronic kidney disease of unknown etiology: an epidemiologic review. Environ Health 2017;16:49. https://doi.org/10.1186/s12940-017-0254- 0.eng
dcterms.referencesMinisterio de Salud y Protección Social. Análisis de inequidades en salud en Colombia. Bogotá D.C: 2022.spa
dcterms.referencesRoveta A, Parodi EL, Brezzi B, Tunesi F, Zanetti V, Merlotti G, et al. Lupus Nephritis from Pathogenesis to New Therapies: An Update. Int J Mol Sci 2024;25. https://doi.org/10.3390/ijms25168981.eng
dcterms.referencesMartínez Ávila MC, Almanza Hurtado AJ, Rodríguez Blanco JD, Rodríguez Yánez T, Daza Arnedo R, Aroca Martínez G. Lupus nephritis, an update. Rev Colomb Reumatol (English Ed 2023;30:250–61. https://doi.org/10.1016/j.rcreue.2023.07.003.eng
dcterms.referencesTeoh STY, Yap DYH, Yung S, Chan TM. Lupus Nephritis and Chronic Kidney Disease: A Scoping Review. Nephrology (Carlton) 2025;30:e14427. https://doi.org/10.1111/nep.14427.eng
dcterms.referencesSales GTM, Macedo NJ, Reis Neto ET Dos, Kirsztajn GM. Current treatment of lupus nephritis: an overview of the new guidelines. J Bras Nefrol 2025;47:e20250092. https://doi.org/10.1590/2175-8239-JBN-2025-0092en.eng
dcterms.referencesDe Geest S, Zullig LL, Dunbar-Jacob J, Helmy R, Hughes DA, Wilson IB, et al. ESPACOMP Medication Adherence Reporting Guideline (EMERGE). Ann Intern Med 2018;169:30–5. https://doi.org/10.7326/M18-0543.eng
dcterms.referencesRitschl V, Stamm TA, Aletaha D, Bijlsma JWJ, Böhm P, Dragoi RG, et al. 2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice. Ann Rheum Dis 2021;80:707–13. https://doi.org/10.1136/annrheumdis-2020-218986.eng
dcterms.referencesHachulla E, Le Gouellec N, Launay D, Balquet M-H, Maillard H, Azar R, et al. Adherence to hydroxychloroquine in patients with systemic lupus: Contrasting results and weak correlation between assessment tools. Jt Bone Spine 2020;87:603–10. https://doi.org/10.1016/j.jbspin.2020.04.017.eng
dcterms.referencesFernández-Avila DG, Accini M, Tobón M, Moreno S, Rodríguez V, Gutiérrez JM. Validación y calibración al español del cuestionario CQR (Compliance Questionnaire on Rheumatology) para la medición de adherencia a la terapia antirreumática en un grupo de pacientes colombianos con artritis reumatoide. Rev Colomb Reumatol 2019;26:105–10. https://doi.org/10.1016/j.rcreu.2019.03.001.eng
dcterms.referencesKidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int 2024;105:S1–69. https://doi.org/10.1016/j.kint.2023.09.002.eng
dcterms.referencesMahieu M, Yount S, Ramsey-Goldman R. Patient-Reported Outcomes in Systemic Lupus Erythematosus. Rheum Dis Clin North Am 2016;42:253–63. https://doi.org/10.1016/j.rdc.2016.01.001.eng
dcterms.referencesSaletra A, Olesińska M. Quality of life in systemic lupus erythematosus and its measurement. Rheumatology 2018;56:45–54. https://doi.org/10.5114/reum.2018.74750.eng
dcterms.referencesMcElhone K, Abbott J, Sutton C, Mullen M, Lanyon P, Rahman A, et al. Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2016;68:1505–13. https://doi.org/10.1002/acr.22850.eng
dcterms.referencesNantes SG, Strand V, Su J, Touma Z. Comparison of the Sensitivity to Change of the 36‐Item Short Form Health Survey and the Lupus Quality of Life Measure Using Various Definitions of Minimum Clinically Important Differences in Patients With Active Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2018;70:125–33. https://doi.org/10.1002/acr.23240.eng
dcterms.referencesCompas BE, Jaser SS, Bettis AH, Watson KH, Gruhn MA, Dunbar JP, et al. Coping, emotion regulation, and psychopathology in childhood and adolescence: A meta-analysis and narrative review. Psychol Bull 2017;143:939–91. https://doi.org/10.1037/bul0000110.eng
dcterms.referencesPrados-Moreno S, Sabio JM, Pérez-Mármol JM, Navarrete-Navarrete N, Peralta-Ramírez MI. Adherencia al tratamiento en pacientes con lupus eritematoso sistémico. Med Clin (Barc) 2018;150:8–15. https://doi.org/10.1016/j.medcli.2017.05.035.eng
dcterms.referencesde Ridder D, Geenen R, Kuijer R, van Middendorp H. Psychological adjustment to chronic disease. Lancet 2008;372:246–55. https://doi.org/10.1016/S0140-6736(08)61078-8.eng
dcterms.referencesWilson TE, Hennessy EA, Falzon L, Boyd R, Kronish IM, Birk JL. Effectiveness of interventions targeting self-regulation to improve adherence to chronic disease medications: a meta-review of meta-analyses. Health Psychol Rev 2020;14:66–85. https://doi.org/10.1080/17437199.2019.1706615.eng
dcterms.referencesParodis I, Studenic P. Patient-Reported Outcomes in Systemic Lupus Erythematosus. Can Lupus Patients Take the Driver’s Seat in Their Disease Monitoring? J Clin Med 2022;11:340. https://doi.org/10.3390/jcm11020340.eng
dcterms.referencesKasturi S, Szymonifka J, Burket JC, Berman JR, Kirou KA, Levine AB, et al. Feasibility, Validity, and Reliability of the 10-item Patient Reported Outcomes Measurement Information System Global Health Short Form in Outpatients with Systemic Lupus Erythematosus. J Rheumatol 2018;45:397–404. https://doi.org/10.3899/jrheum.170590.eng
dcterms.referencesMysler E, Monticielo OA, Al-Homood IA, Lau CS, Hussein H, Chen Y-H. Opportunities and challenges of lupus care in Latin America, the Middle East, and Asia-Pacific: A call to action. Mod Rheumatol 2024;34:655–69. https://doi.org/10.1093/mr/roae001.eng
dcterms.referencesVélez-Verbel M, Aroca-Martínez G, Vélez-Verbel D, Domínguez-Vargas A, Vallejo-Patiño M, Sarmiento-Gutierrez J, et al. Clinical and Immunological Factors Associated with the Progression of Lupus Nephritis in a Population from the Colombian Caribbean. Biomedicines 2024;12. https://doi.org/10.3390/biomedicines12092047.eng
dcterms.referencesStrand V, Simon LS, Meara AS, Touma Z. Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review. Lupus Sci Med 2020;7. https://doi.org/10.1136/lupus-2019-000373.eng
oaire.versioninfo:eu-repo/semantics/acceptedVersion
sb.programaEspecialización en Nefrologíaspa
sb.sedeSede Barranquillaspa

Archivos

Bloque original
Mostrando 1 - 2 de 2
No hay miniatura disponible
Nombre:
Resumen.pdf
Tamaño:
218.83 KB
Formato:
Adobe Portable Document Format
Descargar
No hay miniatura disponible
Nombre:
PDF.pdf
Tamaño:
1.09 MB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
2.93 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Especialización

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca